Total secretory IgA and specific anti-antigen E (AgE) antibodies (ab) in the IgA and IgG classes were measured in concentrated nasal washings from ragweed allergic and normal individuals by antigen binding or anti-alpha-radioimmunoassays. Virtually all the allergic patients had significant IgA (45/49) and IgG (46/49) ab to AgE in their nasal washings. By contrast, washings from most normal persons contained no measurable IgA (13/15) ab or IgG (13/15) ab to AgE. The total IgA levels in allergic washings were not significantly different from those in normal washings and they were used to standardize the ab measurements. Parenteral immunotherapy with ragweed extract increased specific nasal IgA ab from 10.6 +/-2.7 (SEM) to 39.0 +/-8.7 ng AgE bound/mg IgA and IgG ab from 17.2 +/-2.6 to 65.1 +/-7.4 ng AgE bound/mg IgA (P less than 0.001 for both classes). The ratio of IgA:IgG ab was not affected by therapy, and for treated patients, there was no correlation (rs + 0.32, P greater than 0.1) between nasal IgG ab and serum IgG ab. These results suggest that at least part of the nasal IgG ab is produced locally. Blocking activity in the nasal washings was measured by inhibition of histamine release and was found to correlate directly (rs + 0.85, P less than 0.001) with binding activity for AgE. Blocking activity in the nasal washings was measured by inhibition of histamine release and was found to correlate directly (ra + 0.85, P <0.001) with binding activity for AgE. Some washings from normal persons caused slight inhibition of histamine release but others caused enhancement. Nasal washings were fractionated by passage over Sephadex G-200.
INTRODUCTION
It is known that the serum of patients with ragweed hay fever contains IgG (1, 2) and IgA (2) anti-ragweed antibodies (ab) 1 as well as IgE ab (3) . In addition, it has been shown that the serum of patients with ragweed hay fever can 'block' antigen E (AgE)-induced release of histamine from the leukocytes of allergic persons (4) , and that this blocking activity increases with immunotherapy (4) . By contrast, serum from most normal people contains neither blocking activity (4) nor detectable anti-ragweed IgG (1) nor IgE (3) ab. For many years it has been known that there is an increased incidence of allergy in some families (5) and recently it has been reported that there is some association between ragweed hay fever and HL-A type (6, 7) . This pattern of a subpopulation of humans who respond to very small amounts of environmental ragweed antigens (8) with IgE (3) and IgG (1) ab suggests that allergic people are a high-responder population analogous to a high-responder animal strain (9, 10) . If this analogy is correct, nonallergic people must be low responders and they would not be expected to produce anti-ragweed ab of any class in response to environmental exposure.
On the other hand, Turk et al. (11) reported that nasal washings from both allergic and nonallergic persons would inhibit AgE-induced histamine release and they presented some evidence that this blocking activity was mediated by IgA ab. Although subsequently, some nonquantitative data suggested that anti-ragweed ab was not present in nasal washings from nonallergic individuals (12) , more recent results appeared to show that nonallergic individuals have more IgA ab than allergic persons in both their serum (13) and in their nasal washings (14) . These data (13, 14) support the totally different hypothesis that IgA ab protects nonallergic individuals from developing IgE ab, and that the underlying defect in allergic persons is IgA (15) or IgA ab (13) (14) (15) (16) deficiency.
We report here the use of a quantitative radioimmunoassay for IgA-and IgG-AgE binding activity (BA) in nasal washings. Total IgA in the washings was measured using a radioimmunoassay for IgA heavy chain determinants (17) and the BA was then expressed relative to the total IgA. This standardization has made it possible to compare allergic and nonallergic washings and also to quantitate changes in ab during the pollen season and in response to parenteral immunotherapy. In addition, measurements of the blocking of AgE-induced histamine release by nasal washings have been correlated with BA and we have investigated the class distribution of nasal-blocking ab.
METHODS
Monospecific antisera. The preparation of rabbit antisera has been described in detail previously (17) . Briefly, rabbits were immunized with human IgA or IgG in complete Freund's adjuvant (Difco Laboratories, Detroit, Mich.). The anti-IgA was made monospecific by repeated passage over an IgG immunosorbent column and the anti-IgG was made specific for IgG by repeated passage over a Fab immunosorbent column. Human IgG and its Fab component were linked to Sepharose (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) by the cyanogen bromide technique (18) . The gamma-globulin fraction of rabbit antiserum to human secretory piece (SP) was kindly provided by Dr (21) . The nasal washings were diluted where necessary.
A control serum was obtained from a patient who had received very high-dose immunotherapy for several years. The AgE bound by twofold dilutions of this serum from 1/1,920 to 1/480,000 was measured using the assay with anti-IgG and freshly radiolabeled AgE. From the radioactivity bound and the specific activity of the AgE, IgG BA was calculated for each dilution of the serum. This curve was used for all subsequent assays to obtain values for the BA of a given dilution of the control serum. A control curve was set up in parallel with each assay so that the radioactivity bound by nasal washings was first expressed as an equivalent dilution of the control serum, and from this as nanograms of AgE bound per milliliter. The variation between repeated assays of the BA in a given nasal washing was less than +4%. Two nasal washings were found to have high levels of IgA and IgG ab, respectively. Serial twofold dilutions of these washings were assayed for IgA and IgG-BA in parallel with the control serum. The curves were found to be exactly superimposable over the range 0.04-2.0 ng AgE bound/ml, so the serum IgG control curve was used for both IgA-and IgG-nasal ab. From the linear portion of the control serum BA curve it was estimated that the control serum would bind 20.5 ttg AgE/ml. In addition, the BA of the control serum was compared with the BA of a rabbit antiserum to AgE. The antibody activity of the rabbit antiserum had been measured by quantitative precipitation at equivalence, so that the antibody activity of the human control serum could be estimated. From this estimate it was calculated that in antigen excess, the human control serum would bind approximately 24 ,tg AgE/ml. Serum IgG anti-AgE ab was measured by a similar technique using carrier Ig, 'I-labeled AgE, and precipitating with anti-IgG. However, the sera were assayed at several dilutions and the result was given as the reciprocal of the dilution of the serum which bound 50% of a fixed amount of AgE.
For measurement of the AgE binding associated with secretory piece, two modifications of the antigen-binding assay were used. In the Sephadex fractions I and II, sufficient SP was present to give a direct precipitate with anti-SP, equivalence being estimated by immunodiffusion. For the dilution of nasal washings, a triple-antibody technique was used with rabbit (Ra) anti-SP diluted in Ra IgG and finally precipitated by goat anti-Ra IgG. Details of this procedure were described in (17) . In each case, IgA BA was measured in parallel by a similar technique.
Radioimmunoassay for total IgA and IgG. The inhibition radioimmunoassay for human IgA (and IgG) has been fully described elsewhere (17) . Briefly, samples were incubated with anti-IgA (or anti-IgG), diluted in Ra IgG; after 3 h, "MI-labeled IgA (or IgG) was added, and after another 3 h, goat anti-Ra IgG was added to precipitate all the Ra IgG. The precipitate was allowed to form overnight, washed three times with BBS, and the radioactivity in the precipitate was measured with an automatic gamma counter. This assay for IgA avoids the problems of radial immunodiffusion because it detects only IgA heavy chain-determinants and is not affected by variations in diffusion coefficients. When nasal washings or serum IgA were separated on sucrose density gradients, the distribution of IgA detected by the assay showed that the assay could detect monomer or polymer IgA with or without SP (17) . A serum IgA standard was used for this assay, but serial dilutions of nasal washings gave parallel curves over the range 0.2-0.02 gg IgA/ml. All the washings were diluted so as to fall within this range and assays were repeated where necessary.
Assay for blocking of histamine release. The techniques used for in vitro histamine release from human peripheral blood leukocytes were as previously described (11, 22, 23) . The AgE used to stimulate histamine release was kindly provided by Dr. T. P. King (The Rockefeller University, New York) (24) . Two donors were chosen whose cells each released 60-80% of their histamine after challenge with quantities of AgE which we estimated could be bound by the ab in allergic nasal washings. The assay was performed by incubating 0.2 ml of nasal washings at 4°C with 0.2 ml of AgE (1 ng/ml), in tris buffer with albumin, calcium, and magnesium as described previously. After 18 h, 1.0-ml aliquots (-107 cells) of washed human leukocytes were added. The histamine released was measured spectrophotometrically. Results were derived from the percent of histamine release caused by AgE alone (y) and the percent release in the presence of nasal washings (x) using the formula (reference 11):
% inhibition = (y -x/y) X 100. .gE was incu-centrifuged at 10,000 g for 30 min, concentrated, and before adding passed through a Sephadex G-200 column (Fig. 3). patient; hista-Only the early part of the first peak was used (fraction rically. Inhibi-I) to reduce IgG contamination; the second peak (fracn buffer only. tion II) coincided with the elution volume for 5I-,5 (P < 0.001). labeled IgG, and the third peak (fraction III) was (27) . When the fraction of allergic nasal washing-pool were tested by immunodiffusion, the lines seen with anti-IgA and anti-IgG were in keeping with the radioimmunoassay results (Fig. 3) (Table IV) showed a good correlation between BA precipitated by anti-SP and that precipitated by anti-IgA, whereas there was no correlation with the BA precipitated by anti-IgG. In fraction II (Table IV) (25) . Serum was obtained from this group of patients during the ragweed season, and IgG BA was measured in these sera by a 50% binding technique (25) . For these patients the data on nasal BA, serum IgG BA, and clinical symptoms were further analyzed using Spearman rank-correlation. Direct comparison of serum IgG BA with nasal IgG BA (Fig. 4) showed no correlation (r. 0. 32, P > 0.1). Furthermore, neither preseasonal, seasonal, nor postseasonal nasal BA was related to the clinical severity of the patient's ragweed hay fever. Comparing IgA and IgG BA in individual nasal washings revealed a modest correlation (r. 0.56, P <0.05) and this correlation was similar in preseasonal and seasonal specimens.
DISCUSSION
Our results leave no doubt that patients with ragweed hay fever have more IgA and IgG nasal ab to AgE than nonallergic individuals. Not only was the incidence of detectable BA in nasal washings from nonallergic individuals very low (Table I) but we estimate that the average IgA and IgG BA in nasal washings from untreated allergic patients (Table II) was at least 50 times greater than in the fractions of pooled nonallergic nasal washings (Table III) . Only 3 (out of 47) washings from nonallergic individuals contained detectable BA, in 1 case this was IgG alone, in the others both classes were present. No nasal washings from the five normal people who had previously lived in nonragweed infested areas contained detectable BA, but the significance of the data was not affected (P < 0.001) if these washings were excluded. Finding detectable ab in nasal washings from a small proportion of nonallergic individuals is not surprising, as some nonallergic individuals have IgG anti-AgE in their serum.2 The very high incidence of IgG and IgA ab to ragweed in the nasal washings of allergic people (Table I) has been reported before (12) and is in keeping with the finding that all patients with ragweed hay fever have IgG ab to ragweed in their serum (1, 2) .
IgA in the washings was measured by radioimmunoassay; this assay was specific for IgA heavy chain determinants, was much more sensitive than radial immunodiffusion, and has been shown to detect both monomeric and polymeric IgA (17) in secretions or serum.
Expressing nasal BA relative to the total IgA made it possible to compare different washings quantitatively (29) (Table II) . The average concentration of IgA in nasal secretions is, however, five times that of the IgG so that IgA is still quantitatively the most important ab (29) . Immunotherapy increases IgA and IgG BA equally (Table II) . This was surprising as the serum response to immunotherapy is much larger (1) and is predominantly IgG (30) . In addition, we could find no correlation between nasal IgG BA and serum IgG BA in a group of treated patients (Fig. 4) . These findings taken together suggest that nasal IgG BA (as well as IgA BA) does not reflect serum ab and is presumably produced locally; however, our results do not exclude some contribution by transudation of serum ab. The failure of a quantitative correlation between serum and secretory IgG levels may be attributed to individual differences in response. Alternatively, it is possible that immunotherapy might have enhanced the local ab response to environmental antigen. Comparing specimens showed that repeated washings from the same patient before the season have rather consistent levels of IgA BA (Fig. 1) . However, during the season the IgA BA varied widely, including in several cases a sharp dip (Fig. 1) . A rise in BA during or after the season due to environmental exposure was expected and is known to occur with serum IgE ab (25) but these falls are less easy to explain. In many cases IgG BA fell simultaneously which would suggest the possibility that environmental ragweed pollen was neutralizing antiragweed ab, but calculations of the number of pollen grains and their AgE content (nanograms per season) makes direct neutralization unlikely (8) . It is also difficult to see why increasing symptoms should reduce the proportion of a specinic ab unless rhinitis leads to increased transudation of serum IgA which dilutes the local ab. However, transudation in treated patients would be expected to cause an increase in IgG BA which was not observed.
The data in Fig. 2 shows a direct correlation between AgE BA in nasal washings and inhibition of histamine release. Most washings from nonallergic individuals caused enhancement or only slight inhibition (Fig. 2) . On the other hand, a previous report from this laboratory showed that nasal washings from allergic and nonallergic individuals could inhibit AgE-induced histamine release (11) . These results were obtained using leukocytes from highly sensitive patients and very low concentrations of AgE (< 0.2 ng/ml). In preliminary experiments using similar conditions, we found that most washings from nonallergic individuals inhibit histamine release. On the other hand, when using > 4.0 ng of AgE/ml almost all washings from nonallergic individuals enhanced histamine release and only washings with high BA caused inhibition of histamine release. The concentration of AgE used in the present experiments (Fig. 2, Table III ) was chosen to avoid nonspecific inhibition and yet give sufficient sensitivity with low levels of BA. We believe that the inhibition of histamine release previously observed with nasal washings from normal persons (11) was not due to the presence of anti-AgE ab. Since AgE is easily denatured (31) some of the inhibition seen could well represent damage to AgE by enzymes in the nasal washings (32) . With the conditions used in these experiments, most washings from nonallergic individuals enhanced AgE-induced histamine release. A similar enhancement was seen with fractions of the pooled washings from nonallergic individuals. It seems likely that this enhancing effect is similar to the complex enhancing effects of normal serum (33) . And it seems reasonable to assume that the fractions of the pooled allergic washings contain enhancing factors as well as the anti-AgE ab which inhibit histamine release (Table III) . Clearly, nasal washings affect histamine release in multiple ways and it is not surprising that the results of separate experiments show considerable scatter.
Our present results make it clear that nasal washings from allergic patients contain not only IgA and IgG ab, but that both classes of ab can inhibit histamine release. The data suggest that IgA ab inhibits histamine release more effectively than IgG ab (Table III) ; this may reflect higher avidity of polymeric IgA ab. It has previously been reported that the IgA fraction of hyperimmune allergic serum contains very little 'blocking' activity (30) . We reinvestigated the IgA-rich fraction Ha of Lichtenstein et al. (30) and found that it contained little BA of either class but it did contain 140 ,tg/ml of IgA. From those fractions of hyperimmune serum (30) we estimate that serum IgA BA was less than 2% of the IgG BA. Thus, the failure of serum IgA to inhibit histamine release reflects the poor serum IgA ab response to parenteral immunization; and for both serum and nasal washings the ability of fractions to block AgE-induced histamine release correlates well with their BA as measured by radioimmunoassay.
We have shown that the nasal secretions of allergic patients contain more ab than the secretions of nonallergic individuals (1, 2, 4) . However, two recent reports have suggested that allergic patients have less IgA ab in nasal washings (14) and serum (13) than nonallergic individuals. We believe that these results (13, 14) are attributable to an artifact of the immunosorbent system used to measure IgA ab. In our hands it has not proved possible to prepare a ragweed immunosorbent (25) which binds IgA (or IgG) antiragweed ab without binding normal human Ig as well. While it is true that those studies (13, 14) used different antigens, it seems very unlikely that the situation is completely different for grass than for ragweed. Also it is known that rye-grass allergic patients have serum anti-Rye I ab while most nonallergic persons do not.'
Immunotherapy for hay fever is usually less than completely effective at reducing symptoms despite the production of high titers of serum-blocking ab (1, 25, 34) . A possible explanation for this is that the antigen reaches sensitized mast cells in the nose before being exposed to serum ab. That nasal ab would be more effective in controlling hay fever was also suggested by the report (35) that autologous serum-blocking ab applied locally in the nose will reduce symptoms. However, more recent attempts to confirm this finding were not successful (36) . The present study was designed to investigate the role of nasal ab in hay fever and the possible relevance of nasal immunization. We have shown that nasal ab can inhibit histamine release in vitro and that parenteral immunotherapy produces modest increases in nasal ab. It was disappointing that there was no correlation between nasal ab and symptoms of hay fever. However, if nasal ab affects symptoms this would depend on other factors including IgE ab and the sensitivity of basophils or mast cells so that a correlation with nasal ab might be obscured. Further studies are planned to investigate methods for increasing nasal ab and to relate changes in nasal ab to symptoms.
Several theories about the pathogenesis of allergic diseases in man (16) revolve around two possibilities: One, that nonallergic people lack the genetic ability to recognize and respond to allergens at low doses (6, 7, 37) , and two, that in nonallergic people, allergens are prevented from reaching the relevant sites for stimulating the production of IgE ab. It has been postulated that the entry of allergens is prevented by nasal impermeability (16, 38) or by specific nasal IgA ab (13) (14) (15) (16) . Our own data make it most unlikely that nonallergic persons are prevented from becoming allergic by the presence of nasal ab Although some experiments had suggested that nasal permeability was lower in nonallergic individuals (38, 39) , this has not been confirmed by direct experiments (40) . Animal experiments generally show that optimal antigen doses for IgE ab formation will also produce other classes of ab in responding strains (9, 41) but will produce no response of any class in nonresponding strains (9) . Allergic patients produce nasal IgA and IgG ab as well as serum IgG and IgE ab, while no ab is detectable in serum or secretions from most nonallergic individuals. In addition, the doses of pollen antigen encountered environmentally are very low. It therefore seems likely that allergic patients are analogous to a high responder strain (9, 10) and that it is not necessary to propose a nasal block in nonallergic individuals.
